Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

474 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.
Azimi A, Caramuta S, Seashore-Ludlow B, Boström J, Robinson JL, Edfors F, Tuominen R, Kemper K, Krijgsman O, Peeper DS, Nielsen J, Hansson J, Egyhazi Brage S, Altun M, Uhlen M, Maddalo G. Azimi A, et al. Among authors: hansson j. Mol Syst Biol. 2018 Mar 5;14(3):e7858. doi: 10.15252/msb.20177858. Mol Syst Biol. 2018. PMID: 29507054 Free PMC article.
Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A, Tuominen R, Costa Svedman F, Caramuta S, Pernemalm M, Frostvik Stolt M, Kanter L, Kharaziha P, Lehtiö J, Hertzman Johansson C, Höiom V, Hansson J, Egyhazi Brage S. Azimi A, et al. Among authors: hansson j. Cell Death Dis. 2017 Aug 31;8(8):e3029. doi: 10.1038/cddis.2017.406. Cell Death Dis. 2017. PMID: 29048432 Free PMC article.
Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib.
Vidarsdottir L, Fernandes RV, Zachariadis V, Das I, Edsbäcker E, Sigvaldadottir I, Azimi A, Höiom V, Hansson J, Grandér D, Egyházi Brage S, Pokrovskaja Tamm K. Vidarsdottir L, et al. Among authors: hansson j. Melanoma Res. 2020 Oct;30(5):443-454. doi: 10.1097/CMR.0000000000000675. Melanoma Res. 2020. PMID: 32467529 Free PMC article.
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma.
Vidarsdottir L, Azimi A, Das I, Sigvaldadottir I, Suryo Rahmanto A, Petri A, Kauppinen S, Ingvar C, Jönsson G, Olsson H, Frostvik Stolt M, Tuominen R, Sangfelt O, Pokrovskaja Tamm K, Hansson J, Grandér D, Egyházi Brage S, Johnsson P. Vidarsdottir L, et al. Among authors: hansson j. Sci Rep. 2021 May 26;11(1):11023. doi: 10.1038/s41598-021-89389-9. Sci Rep. 2021. PMID: 34040017 Free PMC article.
474 results